| 000 | 01858 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517152735.0 | ||
| 264 | 0 | _c20170620 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1873-2968 | ||
| 024 | 7 |
_a10.1016/j.bcp.2017.04.032 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYue, Xin | |
| 245 | 0 | 0 |
_aIdentification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. _h[electronic resource] |
| 260 |
_bBiochemical pharmacology _c08 2017 |
||
| 300 |
_a29-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aA549 Cells |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemistry |
| 650 | 0 | 4 | _aCHO Cells |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aCricetinae |
| 650 | 0 | 4 | _aCricetulus |
| 650 | 0 | 4 |
_aCurcumin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aDeubiquitinating Enzymes _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Delivery Systems _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aProteasome Endopeptidase Complex _xmetabolism |
| 650 | 0 | 4 |
_aProteasome Inhibitors _xchemistry |
| 700 | 1 | _aZuo, Yinglin | |
| 700 | 1 | _aKe, Hongpeng | |
| 700 | 1 | _aLuo, Jiaming | |
| 700 | 1 | _aLou, Lanlan | |
| 700 | 1 | _aQin, Wenjing | |
| 700 | 1 | _aWang, Youqiao | |
| 700 | 1 | _aLiu, Ziyi | |
| 700 | 1 | _aChen, Daoyuan | |
| 700 | 1 | _aSun, Haixia | |
| 700 | 1 | _aZheng, Weichao | |
| 700 | 1 | _aZhu, Cuige | |
| 700 | 1 | _aWang, Ruimin | |
| 700 | 1 | _aWen, Gesi | |
| 700 | 1 | _aDu, Jun | |
| 700 | 1 | _aZhou, Binhua | |
| 700 | 1 | _aBu, Xianzhang | |
| 773 | 0 |
_tBiochemical pharmacology _gvol. 137 _gp. 29-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bcp.2017.04.032 _zAvailable from publisher's website |
| 999 |
_c27146008 _d27146008 |
||